Burlington, Mass. — November 4, 2025 — Leads & Copy —Abpro Corporation and Celltrion, Inc. will present preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting from November 6–10 in National Harbor, Maryland. The CT-P72/ABP-102 poster was selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025.
The poster, titled “CT-P72/ABP-102: A dual affinity engineered HER2/CD3 tetravalent bispecific antibody with potential to overcome therapeutic barriers in HER2 high tumors with distinct potency, safety, and selectivity,” will be presented by Hyunkyu Choi, Assistant Manager, New Biological Drug Team, Celltrion, Inc.
According to Miles Suk, Chief Executive Officer & Chairman of Abpro, the company is highly encouraged by the preclinical data emerging from their collaboration with Celltrion. Soo Young Lee, Executive Vice President and Head of New Drug Division at Celltrion, Inc. added that CT-P72/ABP-102 represents a significant advance in the field of bispecific antibodies for targeting solid tumors.
Key findings from the study include:
-Selective tumor binding
-Potent, Selective Anti-Tumor Activity
-Strong preclinical activity in vivo including in Enhertu-resistant models
-Favorable Safety Profile
Investor and Media Contact:
Daniel Kontoh-Boateng
DKB Partners, LLC
Tel: +1-862-213-1398
dboateng@dkbpartners.net
Source: Abpro Corporation
